View in EDS HTML Full Text PDF Full Text

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.

Saved in:
Bibliographic Details
Title: Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
Authors: Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Saada-Bouzid E; Department of Medical Oncology, Cote d'Azur University, Centre Antoine Lacassagne, Nice, France., Longo F; Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, Centro de Investigación Biomédica en Red Cáncer, Alcalá University, Madrid, Spain., Yanez E; Oncology-Hematology Unit, University of Frontera, Araucanía, Chile., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Castanon E; Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain., Desautels DN; Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada., Graham DM; Experimental Cancer Medicine Team, The Christie National Health Service Foundation Trust, Manchester, UK.; University of Manchester, Manchester, UK., Garcia-Corbacho J; Clinical Institute of Hemato-Oncological Diseases, Hospital Clinic, Barcelona, Spain., Lopez J; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK., Dutcus C; Eisai Inc., Nutley, New Jersey, USA., Okpara CE; Eisai Ltd., Hatfield, UK., Ghori R; Merck & Co., Inc., Rahway, New Jersey, USA., Jin F; Merck & Co., Inc., Rahway, New Jersey, USA., Groisberg R; Merck & Co., Inc., Rahway, New Jersey, USA., Korakis I; Department of Medicine and Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse, France.
Source: Cancer [Cancer] 2024 Oct 01; Vol. 130 (19), pp. 3278-3288. Date of Electronic Publication: 2024 Jun 21.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39031824
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chung+HC%22">Chung HC</searchLink>; Department of Medical Oncology, Yonsei Cancer Center, Yonsei Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Saada-Bouzid+E%22">Saada-Bouzid E</searchLink>; Department of Medical Oncology, Cote d'Azur University, Centre Antoine Lacassagne, Nice, France.<br /><searchLink fieldCode="AU" term="%22Longo+F%22">Longo F</searchLink>; Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, Centro de Investigación Biomédica en Red Cáncer, Alcalá University, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Yanez+E%22">Yanez E</searchLink>; Oncology-Hematology Unit, University of Frontera, Araucanía, Chile.<br /><searchLink fieldCode="AU" term="%22Im+SA%22">Im SA</searchLink>; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Castanon+E%22">Castanon E</searchLink>; Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Desautels+DN%22">Desautels DN</searchLink>; Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.<br /><searchLink fieldCode="AU" term="%22Graham+DM%22">Graham DM</searchLink>; Experimental Cancer Medicine Team, The Christie National Health Service Foundation Trust, Manchester, UK.; University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Garcia-Corbacho+J%22">Garcia-Corbacho J</searchLink>; Clinical Institute of Hemato-Oncological Diseases, Hospital Clinic, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Lopez+J%22">Lopez J</searchLink>; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.<br /><searchLink fieldCode="AU" term="%22Dutcus+C%22">Dutcus C</searchLink>; Eisai Inc., Nutley, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Okpara+CE%22">Okpara CE</searchLink>; Eisai Ltd., Hatfield, UK.<br /><searchLink fieldCode="AU" term="%22Ghori+R%22">Ghori R</searchLink>; Merck & Co., Inc., Rahway, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Jin+F%22">Jin F</searchLink>; Merck & Co., Inc., Rahway, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Groisberg+R%22">Groisberg R</searchLink>; Merck & Co., Inc., Rahway, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Korakis+I%22">Korakis I</searchLink>; Department of Medicine and Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2024 Oct 01; Vol. 130 (19), pp. 3278-3288. <i>Date of Electronic Publication: </i>2024 Jun 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39031824
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.35387
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3278
    Titles:
      – TitleFull: Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chung HC
      – PersonEntity:
          Name:
            NameFull: Saada-Bouzid E
      – PersonEntity:
          Name:
            NameFull: Longo F
      – PersonEntity:
          Name:
            NameFull: Yanez E
      – PersonEntity:
          Name:
            NameFull: Im SA
      – PersonEntity:
          Name:
            NameFull: Castanon E
      – PersonEntity:
          Name:
            NameFull: Desautels DN
      – PersonEntity:
          Name:
            NameFull: Graham DM
      – PersonEntity:
          Name:
            NameFull: Garcia-Corbacho J
      – PersonEntity:
          Name:
            NameFull: Lopez J
      – PersonEntity:
          Name:
            NameFull: Dutcus C
      – PersonEntity:
          Name:
            NameFull: Okpara CE
      – PersonEntity:
          Name:
            NameFull: Ghori R
      – PersonEntity:
          Name:
            NameFull: Jin F
      – PersonEntity:
          Name:
            NameFull: Groisberg R
      – PersonEntity:
          Name:
            NameFull: Korakis I
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2024 Oct 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 130
            – Type: issue
              Value: 19
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1